期刊文献+

干扰素-γ在放射性肺损伤发生过程中的作用研究 被引量:8

下载PDF
导出
摘要 目的:通过研究大鼠放射性肺损伤模型,探讨干扰素-γ(IFN-γ)在放射性肺损伤的作用及机制,为临床预防和治疗放射性肺损伤提供新的思路。方法:建立Wistar大鼠半胸照射的放射性肺损伤实验动物模型,35只雄性Wistar大鼠随机分为正常对照组(N组),照射组(R1~R3组),照射+药物组(D1~D3组)。其中D1~D3组大鼠在照射后第1天开始腹腔皮下注射IFN-γ5万U/d,至照射后60d停止。每周记录1次Wistar大鼠的临床表现,分别在照射后2、4和12周取材,行常规病理检查,胶原纤维染色,观察IFN-γ对放射性肺损伤的作用。结果:照射后R组与D组体重差异有显著性(P=0.002),D组肺泡炎较R组轻微、发生时间推迟,且进展缓慢(P=0.002),放射性肺纤维程度较R组减弱,但差异无显著性(P=0.137)。D组的Ⅰ型和Ⅲ型胶原的表达显著低于R组(PⅠ型=0.035,PⅢ型=0.040)。结论:IFN-γ在放射性肺损伤的发生过程中抑制了Ⅰ型和Ⅲ型胶原的合成,有效减少了照射后的放疗反应,提高了实验动物在照射后的存活质量,延迟放射性肺泡炎的发生时间并降低其发生的程度。放射性肺纤维化有轻度减弱,可能与随访时间有关。
出处 《实用医学杂志》 CAS 2008年第21期3654-3656,共3页 The Journal of Practical Medicine
基金 南方医科大学南方医院2005年度院长基金资助项目
  • 相关文献

参考文献15

  • 1Szapiel S V, Elson N A, Fulmer J D, et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse [J ]. Am Rev Respir Dis, 1979, 120(4) :893-899.
  • 2Selman M, Thannickal V J, Pardo A, et al. Idiopathic puhnonary fibrosis: Pathogenesis and therapeutic: approaches [J]. Drugs, 2004,64 ( 4 ) : 405 -430.
  • 3Majumdar S, Li D, Ansari T, et al. Different cytokine profiles in cryptogenie fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis:a quantitative study of open lung biopsies [J]. Eur Respir, 1999,14(2) :251-257.
  • 4Graham M V, Matthews J W, Harms W B, et al. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung [Jl. Int J Radiat Oncol Biol Phys, 1994,29(5):1105-1117.
  • 5Visse R, Nagase H. Matrix metalloproteinase sans tissue inhibitors of metalloproteinases: structure, function and biochemistry [J]. Circ Res, 2003,92(8) : 827-839.
  • 6Ruebe C E, Uthe D, Schmid K W, et al. Dose-dependent induction of transforming growth factorβin the hmg tissue of fibrosis-prone mice after thoracic irradiation [J]. Int J Radiat Oncol Biol Phys, 2000,47(4) : 1033-1042.
  • 7D' Ortho M P, Jarreau P H, Delacourt C, et al. Matrix metalloproteinase and elastase activities in LPS-indueed acute lung injury in guinea pigs[J]. AmJ Physiol Lung Cell Mol Physiol, 1994, 266(3 Pt 1):209-216.
  • 8Ferry G, Lonchampt M, Pannel L, et al. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury [J]. FEBS, 1997,402(2-3) : 111-115.
  • 9Atkinson J J, Senior R M. Matrix metalloproteinase-9 in lung remodeling [J]. AmJ Respir Cell Mol BM, 2003,28( 1 ):12-24.
  • 10Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic puhnonary fibrosis [J]. N Engl J Med, 1999,341 ( 17 ) : 1264-1269.

二级参考文献26

  • 1Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and Ⅲ gene expression[J]. Exp Lung Res,1995, 21(5):791
  • 2Wallace WA, Ramage EA, Lamb D, et al. A type-2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis[J]. Clin Exp Immunol,1995,101(3): 436
  • 3Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis[J]. Am J Med Sci, 2001, 322(4):213
  • 4Selman M, King Jr TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and impl ications for therapy[J]. Ann Intern Med, 2001, 134 (2):136
  • 5Mehrnaz GK, Yasuhiro N. Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis[J]. Cytokine,2001,15 (8) :138
  • 6Hagimoto N, Kuwano K, Miyazaki H,et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen[J]. Am J Respir Cell Mol Bio,1997,17(3): 272
  • 7Ando M, Miyazaki E, Fukami T, et al. Interleukin-4-producing cells in idiopathic pulmonary fibrosis: an immunohistochemical study[J]. Respirology,1999, 4(4):383
  • 8Douglas W W,Ryu J H,Schroeder D R et al.Idiopathic pulmonary fibrosis:impact of oxygen and colchicines,prednisone,or no therapy on survival[J].Am J Respir Crit Care Med,2000;161 (4 Pt 1):1172-1178.
  • 9Katzenstein A L,Mayers J.Idiopathic pulmonary fibrosis:clinical relevance of pathologic classification[J].Am J Respir Crit Care Med,1998;157 (4Pt 1):1301-1315.
  • 10Selman M,Thannickal V J,Pardo A et al.Idiopathic pulmonary fibrosis:Pathogenesis and therapeutic approaches[J].Drugs,2004;64:405-430.

共引文献3

同被引文献156

引证文献8

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部